Latest for Narcolepsy Type 1
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Trial sites23 new sites opened for Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With… (Phase 3, Alkermes)ClinicalTrials.gov
- Trial sites2 new sites opened for Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia (Phase 2/3, Takeda)ClinicalTrials.gov
More about Narcolepsy Type 1
Narcolepsy type 1 (NT1) is a chronic neurologic disorder caused by selective loss of hypocretin (orexin)-producing neurons in the lateral hypothalamus, resulting in pathologically low cerebrospinal fluid (CSF) hypocretin-1 levels (typically <110 pg/mL).
Keep reading about Narcolepsy Type 1
The presenting symptom complex includes excessive daytime sleepiness (EDS) with overwhelming sleep tendency, cataplexy (sudden loss of voluntary muscle tone triggered by emotional stimuli such as laughter or surprise), sleep paralysis upon awakening or sleep onset, and hypnagogic or hypnopompic hallucinations.
The pathophysiology appears autoimmune, supported by strong HLA-DQB1*0602 association (present in ~98% of NT1 patients versus 30-40% of general population), recent identification of hypocretin neuron-specific antibodies in some patients, and temporal association with H1N1 infection and vaccination. EDS and cataplexy profoundly impact safety, driving ability, employment, and quality of life.
Under the international sleep disorder criteria (ICSD-3), diagnosis needs daily sleepiness for at least 3 months plus either of 2 findings. One is cataplexy with a daytime nap test (MSLT) showing an average time to fall asleep of 8 minutes or less and REM sleep within 15 minutes of falling asleep in at least 2 naps; a quick REM onset on the overnight sleep study can count as 1 of them. The other is a low hypocretin-1 level in the spinal fluid, 110pg/mL or less. Prognosis is good with treatment; life expectancy is normal.
What are the symptoms of Narcolepsy Type 1?
These are common symptoms of Narcolepsy Type 1, and how strong they are varies from person to person.
- Excessive daytime sleepiness despite adequate nighttime sleep
- Sudden loss of muscle tone triggered by emotion (cataplexy)
- Sleep paralysis
- Hypnagogic/hypnopompic hallucinations
- Fragmented nighttime sleep
- Automatic behaviors during microsleep
Who gets Narcolepsy Type 1?
NT1 typically manifests in adolescence or young adulthood with peak incidence between ages 15-25 years, though presentation can occur as early as childhood or as late as 50 years.
The condition affects males and females equally across all ethnic groups. Strong HLA-DQB1*0602 association is present in virtually all NT1 patients and approximately 25-40% of the general population, indicating that genetic predisposition combined with environmental triggers (possibly H1N1 infection, Pandemrix vaccination, or other infectious agents) is necessary for disease development. HLA-negative NT1 cases are rare.
Geographic variation in HLA haplotype frequencies influences disease prevalence by region. Most cases are sporadic, with no clear inheritance pattern. MedlinePlus Genetics reports that parents, siblings and children of a person with narcolepsy with cataplexy have about 40 times the general population's risk of developing it.
Next steps: find trials you might fitsee approved treatmentsget help payingget alerts
Which medicines are FDA-approved for Narcolepsy Type 1?
There are currently 5 FDA-approved medications for Narcolepsy Type 1.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
Which new Narcolepsy Type 1 medicines are in trials?
Investigational medicines Trial Friend tracks for Narcolepsy Type 1, with trial results, safety findings and where each one stands.
How to get help paying for Narcolepsy Type 1 treatment
Charity funds and drugmaker programs for Narcolepsy Type 1, checked at the source.
- From a charity · NORD RareCareNarcolepsy Medical Assistance fundOpen
Pays for: Medical and medication costs.
The foundation says: “Accepting Applications” - From a charity · NORD RareCareNarcolepsy Premium Copay Assistance fundOpen
Pays for: Insurance premiums and copays.
The foundation says: “Accepting Applications” - From a charity · TotalAssist (formerly PAN Foundation)Narcolepsy fundOpen
Pays for: Out-of-pocket costs for approved medications, up to $5,000 per year. Requires health insurance (any kind).
- From a charity · The Assistance FundNarcolepsy fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
- Wakix (Pitolisant) · WAKIX for You (Harmony Biosciences)
- Xyrem (Sodium oxybate) · JazzCares (Jazz Pharmaceuticals)
- Xywav (Calcium, magnesium, potassium, and sodium oxybates) · JazzCares (Jazz Pharmaceuticals)
- Lumryz (Sodium oxybate for extended-release oral suspension) · RYZUP Support Services (Alkermes)
Every program and fund for Narcolepsy Type 1, by insurance →
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for Narcolepsy Type 1
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Narcolepsy Type 1 resources
Reputable organizations and medical references for learning more about Narcolepsy Type 1, including disease registries, foundation resources, and clinical guidelines.